Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS
Status:
Completed
Trial end date:
2020-06-15
Target enrollment:
Participant gender:
Summary
This Phase IIa pilot study is a placebo controlled, multicenter study to evaluate safety and
efficacy of aerosolized BIO-11006 Inhalation Solution in ARDS patients. The subjects will be
randomized 1:1 to either BIO-11006 125 mg twice daily plus standard of care or placebo plus
standard of care. The treatment will continue for up to 28 days. The study will enroll up to
40 adult ARDS patients in up to eight sites within USA.